Financial statements Notes to the consolidated financial statements continued 35.
Own shares The Employee Benefit Trust EBT of Hikma holds 40,831 2015: 40,831 Ordinary Shares in the Company.
The trustee of the EBT is Capita Trustees Limited, an independent trustee.
The market value of the Ordinary Shares held in the EBT at 31 December 2016 was $1 million 2015: $1 million.
The book value of the retained own shares at 31 December 2016 are $1 million 2015: $1 million.
The Ordinary Shares held in the EBT will be used to satisfy long-term commitments arising from the employee share plans operated by the Company.
Net cash from operating activities 2016 2015 $m $m Profit before tax 210 318 Adjustments for: Depreciation, amortisation, impairment, and write-down of: Property, plant and equipment 78 51 Intangible assets 68 22 Investment in associate 7 Gain on disposal of property, plant and equipment note 5 11 Gain on disposal of intangible assets note 5 18 Movement on provisions 1 3 Cost of equity-settled employee share scheme 22 15 Finance income 12 3 Interest and bank charges 102 57 Results from associates 2 Foreign exchange loss 19 Release of contingent Liability 4 Cash flow before working capital 464 461 Change in trade and other receivables 128 78 Change in other current assets 1 1 Change in inventories 32 4 Change in trade and other payables 46 28 Change in other current liabilities 15 3 Change in other non-current liabilities 3 Cash generated by operations 369 417 Income tax paid 76 51 Net cash generated from operating activities 293 366 The presentation of 2016 has been amended to show the foreign exchange loss in a separate line item.
We have not restated the 2015 comparatives in this respect on the basis that it is only a disclosure as the amount was immaterial and embedded in the net cash generated from operating activities.
Contingent liabilities A contingent liability existed at the balance sheet date in respect of external guarantees and letters of credit totalling $49 million 31 December 2015: $50 million.
In January 2017 the Group received a subpoena from a state attorney general, requesting certain pricing and costing information.
Management do not believe sufficient evidence exists to provide for this currently.
Hikma Pharmaceuticals PLC 188 180 Hikma Pharmaceuticals plc
